Eli Lilly and Co LLY:NYSE
RT Quote | NYSE | USD
Last | 01/27/23 EST
342.10
-5.91 (-1.70%)
-5.91 (-1.70%)Volume
2,204,722
52 week range
231.87 - 384.44
- Open0.00
- Day High0.00
- Day Low0.00
- Prev Close342.10
- 52 Week High384.44
- 52 Week High Date01/24/23
- 52 Week Low231.87
- 52 Week Low Date02/14/22
Key Stats
- Market Cap325.057B
- Shares Out950.18M
- 10 Day Average Volume2.76M
- Dividend4.52
- Dividend Yield1.32%
- Beta0.36
- YTD % Change-6.49
KEY STATS
- Open0.00
- Day High0.00
- Day Low0.00
- Prev Close342.10
- 52 Week High384.44
- 52 Week High Date01/24/23
- 52 Week Low231.87
- 52 Week Low Date02/14/22
- Market Cap325.057B
- Shares Out950.18M
- 10 Day Average Volume2.76M
- Dividend4.52
- Dividend Yield1.32%
- Beta0.36
- YTD % Change-6.49
RATIOS/PROFITABILITY
- EPS (TTM)6.65
- P/E (TTM)51.41
- Fwd P/E (NTM)44.82
- EBITDA (TTM)10.157B
- ROE (TTM)67.69%
- Revenue (TTM)29.239B
- Gross Margin (TTM)75.61%
- Net Margin (TTM)20.63%
- Debt To Equity (MRQ)157.78%
EVENTS
- Earnings Date02/02/2023
- Ex Div Date02/14/2023
- Div Amount1.13
- Split Date-
- Split Factor-
Latest On Eli Lilly and Co
Content From Our Affiliates
Related Video
Profile
MOREEli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta...
David Ricks
Chairman of the Board, President, Chief Executive Officer
Anat Ashkenazi
Chief Financial Officer, Senior Vice President
Address
Lilly Corporate Ctr
Drop Code 1094, Lilly Corporate Ctr
Indianapolis, IN
46285-0001
United States